Ultra-Rapid Virological Response, Young Age, Low γ-GT/ALT-Ratio, and Absence of Steatosis Identify a Subgroup of HCV Genotype 3 Patients Who Achieve SVR with IFN-α(2a) Monotherapy

BACKGROUND AND AIMS: The standard treatment regimen for chronic HCV genotype 3 (HCV-G3) hepatitis consists of PEGylated interferon-α (IFN-α) and ribavirin at varying doses ranging from 400 to 1,200 mg and results in response rates of 80%. However, this therapy has substantial side-effects including...

Descripción completa

Detalles Bibliográficos
Autores principales: Amanzada, Ahmad, Goralczyk, Armin, Moriconi, Federico, Blaschke, Martina, Schaefer, Inga-Marie, van Thiel, David, Mihm, Sabine, Ramadori, Giuliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208815/
https://www.ncbi.nlm.nih.gov/pubmed/21994136
http://dx.doi.org/10.1007/s10620-011-1933-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208815/
https://www.ncbi.nlm.nih.gov/pubmed/21994136
http://dx.doi.org/10.1007/s10620-011-1933-2

Ejemplares similares